switching from branded tirz to compounded gets framed as a like-for-like dose swap and it isn’t, quite. worth flagging for anyone making the jump on insurance grounds. the branded product is a single tirzepatide acetate salt with characterized excipients and a published t1/2 of ~5 days at steady state. compounded versions are usually tirzepatide acetate or sometimes the citrate salt (depends on the 503A pharmacy), reconstituted in BAC water by the user, with a vial concentration the pharmacy picked, not Lilly. three things actually shift: - concentration accuracy. multi-dose vials drawn over 4 wks have measurable peptide degradation, especially if the BAC water ratio is off or storage drifts. real exposure on wk 4 is not the same as wk 1.
salt form. acetate vs citrate has different solubility and theoretically different subcu depot behavior. nobody has run head-to-head PK on humans that I’ve seen published.
injection volume. branded pen delivers a fixed 0.5mL. self-draw at a different concentration changes depot size, which changes absorption kinetics slightly. practical version: don’t assume your old 10mg branded dose = 10mg compounded on the nose. titrate like you’re new. log appetite suppression duration day 1 to day 7 for the first two doses, then compare to your branded baseline if you have it. if day 5-7 hunger return is earlier than before, you’re getting less effective exposure, not more tolerance. schedule fine. compound probably fine. verify, don’t assume.
the concentration degradation point is solid and the titrate-from-scratch advice is correct. but lumping salt form and injection volume in with it as parallel concerns overstates the case. “nobody has run head-to-head PK on humans” on acetate vs citrate is basically an admission that this is theoretical, and depot size differences from 0.5mL vs whatever you self-draw are probably rounding error compared to user-to-user subq technique variation. two of the three factors listed are speculative noise; one (vial accuracy + storage) is real. worth being precise about which risk is which so people don’t treat all three as equally load-bearing.
one thing nobody’s flagged: the excipient profile differs between 503A pharmacies and that’s its own variable separate from salt form. branded zepbound uses sodium chloride, sodium phosphate dibasic heptahydrate, and a specific pH buffer system targeting ~6.5. compounded vials I’ve seen reconstitution sheets for run the gamut, some use plain BAC (0.9% benzyl alcohol in sterile water) with no added buffer, some add L-histidine, some add mannitol as a stabilizer. this matters because tirzepatide aggregation kinetics are pH-sensitive. the GLP-1/GIP backbone has known instability outside ~pH 6-7.5 and aggregation isn’t always visible. you can have hazy-free liquid that’s lost 10-20% monomer to soluble aggregates and the patient sees nothing weird in the vial. related: there’s published stability data on semaglutide showing measurable monomer loss at room temp over 28 days even in the branded formulation, and tirz is structurally more aggregation-prone bc of the lipid tail. compounded with imperfect buffering and 4 weeks of fridge cycling (door opens, temp swings 2-8C to maybe 10C briefly, back down) is going to be worse than that baseline. practical add to the OP framework: if you’re on compounded and notice your day 1 post-injection appetite suppression is fine but the wk 4 vial of the same lot feels weaker, that’s not tolerance and it’s not necessarily concentration drift from evaporation. it could be aggregation from an under-buffered formulation that degraded over the dosing month. switching to a different 503A and seeing the same pattern repeat = formulation issue. switching and the pattern resolves = your old pharmacy’s buffer system is the problem. the way to actually catch this n=1 is log the time-to-hunger-return on injection day across the full 4-week vial life. if there’s a downward trend from week 1 to week 4 dose, formulation stability is your suspect. if it’s flat across the vial but lower than branded baseline, salt form or concentration accuracy is more likely. ymmv, not a clinician, ask yours.
Worth adding to the variable pile: silicone oil shed from standard insulin syringe barrels is a documented nucleation site for protein aggregation, there’s solid work on this in the monoclonal antibody literature. Every self-draw picks up trace amounts the branded pen never introduces. Small effect probably, but layered onto under-buffered formulation and four weeks of thermal cycling, it’s one more reason the tracking approach you’ve outlined is worth doing with care.
the steel-man on titrating like you’re new is sound, but the day 5-7 hunger return heuristic conflates exposure with receptor response. ime appetite signal drifts with sleep and cycle phase enough that one bad week reads like underdosing when it isn’t. log two cycles before you change anything.
the salt-form bullet is the one I’d lean on hardest. acetate vs citrate isn’t just a solubility footnote, it changes local pH at the depot and theoretically the rate of fibrillation/aggregation in the vial over those 4 weeks, which compounds (sorry) with your degradation point. fwiw the closest analog data I’ve seen is older insulin glargine work where citrate buffering shifted Tmax noticeably, not a perfect parallel but the principle holds. the “log day 1 to day 7 hunger return” advice is also the right move because that’s the cheapest readout of effective exposure anyone has access to without an assay. titrate like you’re new, agreed.